
|Videos|October 9, 2017
Neoadjuvant Therapy for HER2+ Early Breast Cancer
Neoadjuvant Therapy for HER2+ Early Breast Cancer
Advertisement
- A 53-year-old woman was referred to a breast surgeon after finding a mass in her left breast
- PMH: unremarkable
- FH: no history of cancer in first-degree relatives
- PE: revealed a 6 X 5-cm, non-fixed mass in the left inferior breast without skin changes or nipple discharge, and palpable lymphadenopathy in the left axilla
- ROS: clear
- Mammogram confirmed a left-sided, poorly defined spiculated mass. Ultrasound shows a 5.3-cm solid mass and enlargement of 2 left axillary nodes with thickened cortex
- Pathology results:
- Core needle biopsy from the breast mass confirmed grade 3 invasive ductal carcinoma
- ER,PR,HER2IHC 3+
- FISH,HER2copy number, 15;HER2:CEP17 ratio, 7
- Fine-needle aspiration of one left axillary lymph nodes was positive for carcinoma
- Core needle biopsy from the breast mass confirmed grade 3 invasive ductal carcinoma
- Staging: T2bN1M0
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































